Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382: 810-821
Published: 29th April 2020
Authors: Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J et al.
Conclusion
A total of 602 women took part in the first interim analysis. Complete pathological response was 64.8 per cent with additional pembrolizumab, compared to 51.2 per cent in women having standard neoadjuvant chemotherapy (p<0.001).
Pubmed LinkYou may also be interested in
Scientific Surgery
Authors: Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R et al.
Scientific Surgery
Authors: Papakonstantinou A, Matikas A, Bengtsson NO, Malmstrom P, Hedayati E, Steger G et al.
Scientific Surgery
Authors: Gralow JR, Barlow WE, Paterson AHG, M’iao JL, Lew DL, Stopeck AT et al.
Scientific Surgery
Authors: Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ et al.
Scientific Surgery
Authors: Su Y, Huang J, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y et al.
Scientific Surgery
Authors: Yu K-D, Wu S-Y, Liu G-Y, Wu J, Di G-H, Hu Z et al.
Scientific Surgery
Authors: Nitz M, Gluz O, Clemens M, Malter W, Reimer T, Nuding B et al.
Scientific Surgery
Authors: Whelan TJ, Julian JA, Berrang TS, Kim D-H, Germain I, Nichol AM et al.
Scientific Surgery
Authors: Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA et al.
Scientific Surgery
Authors: Cuzik J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE et al.
Scientific Surgery
Authors: Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C et al.
Scientific Surgery
Authors: Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertson B, de Azambuja E et al.